Skip to main content

Advertisement

SpringerLink
Log in

Nilotinib-induced interstitial lung disease

  • Case Report
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Nilotinib is a second-generation tyrosine kinase inhibitor active in patients with chronic myeloid leukemia (CML) resistant to imatinib, and has been recently approved for newly diagnosed patients. We present a case of nilotinib-induced interstitial lung disease (ILD). A 67-year-old female patient was initially treated with imatinib for chronic-phase Philadelphia chromosome-positive (Ph+) CML. Imatinib was replaced by nilotinib because of hematological toxicity. The patient had received nilotinib for about 3 years without significant adverse effects. She visited the clinic due to chronic cough; chest X-ray revealed consolidations in both lung fields. Nilotinib-induced ILD was diagnosed based on intensive workup, including lung biopsy. She responded dramatically to corticosteroid therapy. To our knowledge, this is the first reported case of nilotinib-induced ILD in a patient with Ph+ CML. We emphasize that if unexplained lung abnormalities progress in patients receiving nilotinib, physicians should consider this potentially fatal complication in their differential diagnoses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011;117:1141–5.

    Article  PubMed  CAS  Google Scholar 

  2. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251–9.

    Article  PubMed  CAS  Google Scholar 

  3. Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12:841–51.

    Article  PubMed  CAS  Google Scholar 

  4. Bergeron A, Rea D, Levy V, Picard C, Meignin V, Tamburini J, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med. 2007;176:814–8.

    Article  PubMed  CAS  Google Scholar 

  5. Radaelli F, Bramanti S, Fantini NN, Fabio G, Greco I, Lambertenghi-Deliliers G. Dasatinib-related alveolar pneumonia responsive to corticosteroids. Leuk Lymphoma. 2006;47:1180–1.

    Article  PubMed  CAS  Google Scholar 

  6. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260–70.

    Article  PubMed  CAS  Google Scholar 

  7. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531–41.

    Article  PubMed  CAS  Google Scholar 

  8. Swords R, Mahalingam D, Padmanabhan S, Carew J, Giles F. Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. Drug Des Devel Ther. 2009;3:89–101.

    PubMed  CAS  Google Scholar 

  9. Delomas T, Darne C, Besson C. Lack of recurrence of imatinib-induced interstitial lung disease with nilotinib. Leuk Lymphoma. 2012;53:332–3.

    Article  PubMed  CAS  Google Scholar 

  10. Ohnishi K, Sakai F, Kudoh S, Ohno R. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia. 2006;20:1162–4.

    Article  PubMed  CAS  Google Scholar 

  11. Ma CX, Hobday TJ, Jett JR. Imatinib mesylate-induced interstitial pneumonitis. Mayo Clin Proc. 2003;78:1578–9.

    Article  PubMed  Google Scholar 

  12. Rosado MF, Donna E, Ahn YS. Challenging problems in advanced malignancy: case 3, imatinib mesylate-induced interstitial pneumonitis. J Clin Oncol. 2003;21:3171–3.

    Article  PubMed  Google Scholar 

  13. Yamasawa H, Sugiyama Y, Bando M, Ohno S. Drug-induced pneumonitis associated with imatinib mesylate in a patient with idiopathic pulmonary fibrosis. Respiration. 2008;75:350–4.

    Article  PubMed  Google Scholar 

  14. Quintas-Cardama A, Kantarjian H, O’Brien S, Borthakur G, Bruzzi J, Munden R, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25:3908–14.

    Article  PubMed  CAS  Google Scholar 

  15. Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007;109:5143–50.

    Article  PubMed  CAS  Google Scholar 

  16. Rajda J, Phatak PD. Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy. Am J Hematol. 2005;79:80–1.

    Article  PubMed  Google Scholar 

  17. Wagner U, Staats P, Moll R, Feek U, Vogelmeier C, Groneberg DA. Imatinib-associated pulmonary alveolar proteinosis. Am J Med. 2003;115:674.

    Article  PubMed  Google Scholar 

  18. Bergeron A, Bergot E, Vilela G, Ades L, Devergie A, Esperou H, et al. Hypersensitivity pneumonitis related to imatinib mesylate. J Clin Oncol. 2002;20:4271–2.

    Article  PubMed  CAS  Google Scholar 

  19. Lin JT, Yeh KT, Fang HY, Chang CS. Fulminant, but reversible interstitial pneumonitis associated with imatinib mesylate. Leuk Lymphoma. 2006;47:1693–5.

    Article  PubMed  Google Scholar 

  20. Grimison P, Goldstein D, Schneeweiss J, Murray N. Corticosteroid-responsive interstitial pneumonitis related to imantinib mesylate with successful rechallenge, and potential causative mechanisms. Intern Med J. 2005;35:136–7.

    Article  PubMed  CAS  Google Scholar 

  21. Izumiyama N, Noguchi K, Takahashi H, Shishikura Y, Saitou W, Nishimaki K, et al. Successful reintroduction of mesylate imatinib after pneumonitis in two patients with gastrointestinal stromal tumor (GIST). Nihon Kokyuki Gakkai Zasshi. 2009;47:918–23.

    PubMed  Google Scholar 

  22. Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration. 2004;71:301–26.

    Article  PubMed  Google Scholar 

  23. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood. 2000;95:90–5.

    PubMed  CAS  Google Scholar 

  24. Breccia M, Latagliata R, Carmosino I, Cannella L, Diverio D, Guarini A, et al. Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicin. Haematologica. 2008;93:1918–20.

    Article  PubMed  Google Scholar 

  25. Eisen T, Sternberg CN, Robert C, Mulders P, Pyle L, Zbinden S, et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst. 2012;104:93–113.

    Article  PubMed  CAS  Google Scholar 

  26. Yokoyama T, Miyazawa K, Kurakawa E, Nagate A, Shimamoto T, Iwaya K, et al. Interstitial pneumonia induced by imatinib mesylate: pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration. Leukemia. 2004;18:645–6.

    Article  PubMed  CAS  Google Scholar 

  27. Snyder LS, Hertz MI, Peterson MS, Harmon KR, Marinelli WA, Henke CA, et al. Acute lung injury: pathogenesis of intraalveolar fibrosis. J Clin Invest. 1991;88:663–73.

    Article  PubMed  CAS  Google Scholar 

  28. Walsh J, Absher M, Kelley J. Variable expression of platelet-derived growth factor family proteins in acute lung injury. Am J Respir Cell Mol Biol. 1993;9:637–44.

    Article  PubMed  CAS  Google Scholar 

  29. Dao K, Vedy D, Lopez J, Staneczek O, Buclin T, Livio F. Imatinib-induced dose-dependent interstitial lung disease successfully switched to nilotinib: a case report with concentration exposure data. Int J Hematol. 2013;97:299–300.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Hematology-Oncology, Department of Internal Medicine, Gyeongnam Regional Cancer Center, Institute of Health Sciences, Gyeongsang National University School of Medicine, 90 Chilam-dong, Jinju, 660-702, Korea

    Se-Il Go, Won Sup Lee, Gyeong-Won Lee, Jung Hun Kang, Myung Hee Kang & Hoon-Gu Kim

  2. Department of Pathology, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju, Korea

    Jeong-Hee Lee

Authors
  1. Se-Il Go
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Won Sup Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gyeong-Won Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jung Hun Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Myung Hee Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jeong-Hee Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hoon-Gu Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hoon-Gu Kim.

About this article

Cite this article

Go, SI., Lee, W.S., Lee, GW. et al. Nilotinib-induced interstitial lung disease. Int J Hematol 98, 361–365 (2013). https://doi.org/10.1007/s12185-013-1398-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-013-1398-5

Keywords

Search

Navigation